Real-World Alcohol Use Disorder Outcomes in PatientsWith Concurrent Metabolic Dy
A recent study shows that GLP-1 receptor agonists are associated with a 45% lower rate of one-year AUD relapse compared to naltrexone in patients with concurrent metabolic dysfunction.
GLP-1 Receptor Agonists: Metabolic Health Risks in Youth
GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical TrialObservational StudyPediatric ObesityInsulin ResistanceEndocrinologyChildren and…
GLP-1 Cardiovascular Outcomes: Metabolic Health Phenotypes
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical ReviewObservational StudyCentral ObesityInsulin ResistanceCardiologyAdults…
GLP-1 Receptor Agonist Safety in Women’s Hormonal Health
GLP-1 Clinical Relevance #41Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservational StudyPolycystic Ovary SyndromeGLP-1 Receptor…
GLP-1 Receptor Agonist Clinical Evidence on Optimal Body Fat
GLP-1 Clinical Relevance #44Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservational StudyMetabolic HealthInsulin ResistanceEndocrinologyAdults…
Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration.
Cannabidiol (CBD) and cannabigerol (CBG) are non-psychoactive phytocannabinoids with emerging therapeutic potential in metabolic dysfunction-associated steat...